Losing inches but not weight on Wegovy — is that normal?

The myth: if the scale hasn't moved, nothing has changed

This is the most common misreading of early Wegovy progress, and it causes real frustration. The scale measures total mass, fat, muscle, bone, organ tissue, water, the contents of your digestive tract. It cannot distinguish between them. Semaglutide works primarily by reducing appetite, slowing gastric emptying and shifting how your body uses stored energy. The result is a gradual reduction in adipose tissue. Fat, however, is far less dense than muscle or water. A substantial loss of fat volume can produce a measurable change in waist, hip or thigh circumference while the total number on the scale barely shifts.

Clinical trials support this. In the STEP 1 trial, published in the New England Journal of Medicine, participants on 2.4mg semaglutide lost an average of around 15% of body weight over 68 weeks, but body composition changes (fat versus lean mass) were also reported, underlining that weight is a lagging indicator of what's actually shifting inside your body. If you're losing inches but not weight on semaglutide, you're almost certainly in the middle of a genuine fat-loss process that the scale hasn't caught up with yet, which is something our page on how semaglutide supports losing weight explains in more detail.

It's worth saying plainly: reaching this point and feeling confused by the numbers is completely understandable. Most of us have spent years equating weight with progress. Unlearning that takes a moment.

Three things that keep the scale still while fat disappears

Fat density is around 0.9 g/cm³; skeletal muscle sits closer to 1.06 g/cm³. If Wegovy has reduced your appetite and you've naturally become a little more active (walking further, carrying shopping more easily) there's a reasonable chance you've added a small amount of lean mass at the same time as losing fat. The net weight change can be close to zero. Your waistband, though, notices the difference immediately because fat takes up far more space per gram.

Water retention is the second culprit. Hormonal fluctuations, changes in dietary sodium, inadequate hydration and ordinary stress all cause the body to hold onto fluid. A litre of water weighs one kilogram. On any given morning, fluid shifts alone can swing the scale by one to two kilograms in either direction, completely independent of fat loss. This is why a single weigh-in tells you almost nothing, and why clinicians on any structured weight-management programme typically ask patients to weigh at the same time of day, on the same surface, after the same morning routine, and to track a rolling average rather than a daily reading.

A third factor is glycogen. When carbohydrate intake drops (which often happens naturally as appetite falls on Wegovy) the body depletes its glycogen stores. Each gram of glycogen binds roughly three grams of water. Losing glycogen initially drops weight quickly; rebuilding it (if carbohydrate intake rises again) adds it back, independently of fat. None of this is fat gain. It's storage chemistry.

How long does this pattern last, and when should you talk to a prescriber?

For most people, the inches-without-weight-loss phase is temporary. As fat loss continues, the cumulative change eventually outpaces any offsetting lean-mass or fluid shifts, and the scale begins to move. The overall weight-loss trajectory on Wegovy tends to be gradual and non-linear: plateaus, slow weeks and the occasional frustrating fortnight are part of the normal pattern. A static scale for two or three weeks alongside continuing inch loss is not a reason to change doses or stop treatment, though if you're wondering whether weight loss can stall or stop altogether on this medication, our guide on whether you can stop losing weight on Wegovy covers what the evidence says.

That said, if several months pass without any change in either measurement and you're on a maintenance dose, that's worth raising with whoever prescribed your treatment. The NHS patient guidance on semaglutide advises keeping in contact with your clinical team throughout treatment; this is exactly the kind of question a prescriber should hear rather than you quietly worrying about it. Under NICE's guidance, continuing treatment is reviewed if weight loss falls below 5% after six months at the highest tolerated dose, so there is a formal checkpoint built into the process.

In practical terms: keep measuring. A tape measure around the waist, hips and thighs taken monthly gives you trend data that a daily scale reading cannot. Clothing is an imperfect but honest signal too. If the trousers are looser, something real is happening, whatever the digital display says.

Tracking progress more usefully during treatment

A multi-measure approach is the most sensible way to monitor what semaglutide is doing. Waist circumference is particularly relevant from a health perspective, visceral fat (the kind stored around the abdomen) carries the most metabolic risk, and it tends to respond to treatment before subcutaneous fat does. A shrinking waist is therefore both a cosmetic and a clinical signal worth recording.

Some people find it helpful to photograph progress monthly in consistent conditions (same lighting, same time of day) rather than stepping on a scale daily. Others prefer to track energy levels, sleep quality or how much they can walk without discomfort. All of these capture dimensions of progress that a number on a scale ignores completely.

If you're thinking about what happens to body composition after stopping Wegovy, or wondering whether a slower scale response means your treatment plan needs adjusting, that conversation belongs with a clinician who knows your full picture. For context on what private Wegovy treatment involves and costs, the Wegovy pricing page covers what's included. And if you'd like a prescriber to review where you are in your treatment, speaking to our prescribers is the straightforward next step.